2026-01-26 - Analysis Report
**Company Overview**
Regeneron Pharmaceuticals is a biopharmaceutical company that researches, develops, and commercializes drugs and treatments for various diseases.

**Comparison of Return Rate**
|    | Cumulative Return |
|---|--------------------|
| REGN | 50.26% |
| VOO  | 126.41% |
| Divergence | -75.30 |
| Relative Divergence | 21.00% |

The cumulative return of REGN is significantly lower than that of VOO, with a divergence of -75.30. This suggests that REGN has underperformed the S&P 500 in the given period.

**Alpha, Beta Analysis**
| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | -3.0% | 24.1% | -15.0% | 1.2 | 39.6B |
| 2017-2019  | 9.0% | 27.3% | -17.0% | 1.0 | 39.8B |
| 2018-2020  | 31.0% | 27.3% | 7.0% | 0.7 | 51.2B |
| 2019-2021  | 40.0% | 27.3% | -26.0% | 0.6 | 66.9B |
| 2020-2022  | 72.0% | 25.7% | 66.0% | 0.6 | 76.5B |
| 2021-2023  | 61.0% | 24.4% | 40.0% | 0.6 | 93.1B |
| 2022-2024  | -1.0% | 40.5% | -30.0% | 0.6 | 75.5B |
| 2023-2025  | -17.0% | 57.2% | -92.0% | 0.6 | 81.8B |

The CAGR and MDD values indicate a volatile performance of the company. The Alpha and Beta values suggest that the company's stock has historically offered a relatively stable risk profile.

**Recent Stock Price Fluctuations**
|    | Close | 5-day SMA | 20-day SMA | 60-day SMA |
|---|-------|------------|-------------|-------------|
|  | $753.55 | $745.04 | $768.45 | $732.28 |

The recent stock price has been declining, with the 5-day SMA indicating a sharp rebound.

**RSI, PPO, and Market Risk Indicator (MRI) Analysis**
|    | RSI | PPO | MRI |
|---|-----|-----|-----|
|    | 43.14 | -0.70 | 0.70 |

The RSI and PPO values indicate a potential oversold situation. The MRI is at a medium level, suggesting a balance of risk and reward.

**Relative Divergence Change**
Recent (20 days) relative divergence change: 2.10 (+): improving

The relative divergence is improving, indicating a potential reversal in the trend.

**Expected Return**
|    | Expected Return |
|---|----------------|
|    | 8.70% |

The expected return is 8.70%, indicating a potential long-term growth opportunity.

**Recent News & Significant Events**
1. [2026-01-23] REGN or ILMN: Which Is the Better Value Stock Right Now? - Yahoo Finance
2. [2026-01-02] Regeneron Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on January 30, 2026 - Quiver Quantitative
3. [2026-01-25] What Regeneron Pharmaceuticals (REGN)'s Eylea HD Progress and STEM Investment Push Means For Shareholders - simplywall.st
4. [2026-01-11] A big Wall Street flip just changed the Regeneron narrative - thestreet.com
5. [2026-01-23] Regeneron (REGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Finviz
6. [2026-01-25] Resona Asset Management Co. Ltd. Sells 5,371 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

These recent news and events indicate a potential shift in the company's narrative and a possible upward trend in the stock price.

**Analyst Opinions**
Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 1.69 (~Buy)
- Opinions: 26
- Target Price (avg/high/low): 830.04 / 1057.00 / 630.00

The analyst opinions indicate a strong buy rating and a potential upward target price.

**Recent Earnings Analysis**
| Date | EPS | Revenue |
|------|-----|----------|
| 2025-10-28 | 14.09 | 3.75 B$ |
| 2025-08-01 | 13.24 | 3.68 B$ |
| 2025-04-29 | 7.58 | 3.03 B$ |
| 2024-10-31 | 12.4 | 3.72 B$ |
| 2025-10-28 | 12.4 | 3.72 B$ |

The recent earnings data indicate a strong growth performance, with a significant increase in revenue and EPS.

**Financial Information - Revenue and Profitability**
| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $3.75B | 86.11% |
| 2025-06-30 | $3.68B | 85.58% |
| 2025-03-31 | $3.03B | 84.67% |
| 2024-12-31 | $3.79B | 85.08% |
| 2024-09-30 | $3.72B | 86.80% |

The revenue and profit margin data indicate a strong growth trend, with a significant increase in revenue and profit margin.

**Financial Information - Capital and Profitability**
| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $30.96B | 4.72% |
| 2025-06-30 | $29.94B | 4.65% |
| 2025-03-31 | $29.39B | 2.75% |
| 2024-12-31 | $29.35B | 3.13% |
| 2024-09-30 | $29.33B | 4.57% |

The equity and ROE data indicate a stable capital base and a relatively stable return on equity.

**Comprehensive Analysis (Summary of previous items)**
The comprehensive analysis indicates a mixed performance of Regeneron Pharmaceuticals, with a strong growth trend in revenue and EPS, but a volatile performance of the stock price. The analyst opinions indicate a strong buy rating and a potential upward target price. The recent news and events indicate a potential shift in the company's narrative and a possible upward trend in the stock price.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.